44 results
6-K
EX-1.1
IPHA
Innate Pharma
6 Feb 24
Current report (foreign)
5:05pm
in all material respects with said rule.
All information and other disclosure materials made publicly available by the Company are true, complete
424B5
IPHA
Innate Pharma
6 Feb 24
Prospectus supplement for primary offering
5:00pm
products, media or critical raw materials), (c) research and development activities related to critical technologies (including cybersecurity, artificial … , space, telecom, public health, farm products, media or critical raw materials), (c) research and development activities related to critical
F-3
o2prk8qww8
20 Dec 23
Shelf registration (foreign)
4:45pm
6-K
EX-99.2
x6i5w r49fl3ps3nj
14 Sep 23
Innate Pharma Reports First Half 2023 Financial Results and Business Update
6:27am
6-K
EX-1.1
p4evo30ltd1jtj8vfpd
26 Apr 23
Current report (foreign)
4:02pm
424B5
yznz5s0k
26 Apr 23
Prospectus supplement for primary offering
4:01pm
20-F/A
EX-4.9
7erz2
20 Apr 23
Annual report (foreign) (amended)
8:47am
6-K
EX-99.2
8p7oq72ixqkmv llc09y
15 Sep 22
Innate Pharma Reports First Half 2022 Financial Results and Business Update
6:12am
6-K
EX-1.1
cw1t5po1dpsjm3g3a
3 May 22
Current report (foreign)
5:08pm
424B5
6xosdsk5x7ett5
3 May 22
Prospectus supplement for primary offering
4:36pm
6-K
EX-99.2
9qp2jjt9 pe7ffa
15 Sep 21
Innate Pharma Reports First Half 2021 Financial Results and Business Update
6:07am
F-3
smpiwl0y3szv0gp1584
13 Jan 21
Shelf registration (foreign)
1:59pm
6-K
EX-99.2
8k6vy ttms6i
8 Sep 20
Innate Pharma Reports First Half 2020 Financial Results and Business Update
6:10am
6-K
EX-99.1
uzcyg818cgng6 xx5
20 May 20
Pascale Boissel appointed new member of Innate’s Supervisory Board
6:30am